Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SeaStar Medical Holding Corporation (Nasdaq: ICU) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy statements, and other documents filed with the U.S. Securities and Exchange Commission. These filings give investors detailed information about SeaStar Medical’s commercial-stage healthcare business built around its Selective Cytopheretic Device (SCD) therapy and QUELIMMUNE (SCD-PED) product for pediatric acute kidney injury (AKI).
Through Form 8-K current reports, SeaStar Medical discloses material events such as the recommendation of an independent Data Safety Monitoring Review Board to continue the NEUTRALIZE-AKI pivotal trial with zero device-related safety issues, changes in executive leadership, and corporate actions like the approval and implementation of a 1-for-10 reverse stock split to adjust the company’s share structure while maintaining its Nasdaq listing. These filings also describe adjustments to clinical trial enrollment targets and other operational updates.
The company’s DEF 14A proxy statements provide details on matters submitted to stockholders, including proposals related to reverse stock splits and authorized share counts. They outline voting procedures, meeting logistics, and the rationale behind capital structure decisions. Together with other periodic and transactional filings, these documents help explain how SeaStar Medical manages its equity, governance, and financing as it advances SCD-based therapies.
On Stock Titan, SeaStar Medical’s filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the key points in complex filings, helping readers quickly understand topics such as trial-related disclosures, compensation arrangements for executives, and the impact of corporate actions on ICU common stock and ICUCW warrants. Users can also review filings that reference the company’s Breakthrough Device Designations, Humanitarian Device Exemption framework for QUELIMMUNE, and pivotal trial plans, gaining a structured view of how regulatory and clinical developments intersect with SeaStar Medical’s capital markets activity.
SeaStar Medical Holding Corp (ICU) Form 3 filed by Bradford K. Towne reports beneficial ownership of 15,500 shares of common stock. The filing is an initial statement under Section 16 and reflects stock awards rather than open-market purchases.
The 15,500 shares include 5,000 restricted stock units (RSUs) from an April 12, 2024 grant of 8,000 RSUs that vest monthly through February 2028 and 7,500 RSUs granted April 1, 2025 that vest in three equal tranches on April 1, 2026, 2027 and 2028. Towne is identified as the issuer's Principal Accounting Officer. The event date triggering the report is 08/26/2025 and the form is signed on 09/09/2025.
SeaStar Medical Holding Corp (ICU) director Kenneth Van Heel reported open-market purchases totaling 35,000 shares across two days. On 08/26/2025 he acquired 25,000 shares at a weighted-average price of $0.8899, increasing his direct holdings to 39,400 shares. On 08/27/2025 he acquired 10,000 shares at a weighted-average price of $0.8565, raising his direct holdings to 49,400 shares.
The Form 4 shows these were non-derivative purchases and that no derivative securities were reported. The filing was submitted by an attorney-in-fact on 08/28/2025.
SeaStar Medical insider purchase: Chief Medical Officer Kevin Chung purchased 10,000 shares of SeaStar Medical Holding Corp (ICU) on 08/22/2025 at a reported price of $0.80 per share, increasing his beneficial ownership to 58,184 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025. No derivative transactions or additional remarks were reported.
SeaStar Medical Holding Corporation reported that its Board ended the employment of Chief Financial Officer and Treasurer David Green on August 13, 2025, effective August 14, 2025. The termination is described as being without “Cause” under his employment agreement. Subject to a mutually agreeable separation and release agreement, the company expects to pay him approximately $300,000 in base salary over 12 months, cover up to 18 months of COBRA health insurance premiums if elected, and accelerate vesting of his unvested restricted stock units.
On August 19, 2025, the Board appointed CEO Eric Schlorff as principal financial officer, interim Chief Financial Officer and Treasurer while a search for a permanent CFO is conducted. The Board also named Bradford Towne, age 48 and the company’s Controller since February 2024, as principal accounting officer. Towne has prior senior accounting roles at JAL Equity, Aytu BioPharma, and Gevo, and previously spent 10 years in KPMG’s audit practice.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting collective beneficial ownership of 1,466,096 shares of SeaStar Medical Holding Corp common stock, equal to 4.99% of the class. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that Armistice exercises voting and investment power over the Master Fund's holdings; Mr. Boyd, as managing member, is similarly reported. The submission characterizes the position as held in the ordinary course of business and not for the purpose of changing or influencing control.
SeaStar Medical Holding Corporation filed an amendment to its current report to correct an inadvertent EDGAR submission header so the filing references Items 2.02 and 9.01. The amendment states it makes no changes to the substance of the original report.
The original report furnished a press release as Exhibit 99.1 announcing the company's financial condition and results for the three and six months ended June 30, 2025.
SeaStar Medical Holding Corporation (ICU) reported early commercial sales of its pediatric SCD product QUELIMMUNE, recognizing $338 thousand in revenue for the quarter and $631 thousand for the six months ended June 30, 2025. Gross profit was $311 thousand for the quarter and $604 thousand for six months; cost of goods sold was $27 thousand. The company recorded a net loss of $2.0 million for the quarter and $5.8 million for the six months, with a weighted-average share base of 11.33 million and basic and diluted net loss per share of $(0.18) and $(0.58), respectively.
The balance sheet shows $6.3 million in cash and $8.4 million in total assets as of June 30, 2025, and an accumulated deficit of $145.3 million. Management states it does not believe existing cash is sufficient to fund operations for 12 months and discloses substantial doubt about going concern. The filing details multiple 2025 equity financings (February, June, ATM proceeds) and subsequent July/August 2025 registered offerings, and notes receipt of a Nasdaq notice for bid-price noncompliance with a cure period to January 27, 2026.
Three reporting persons — Ayrton Capital LLC, Alto Opportunity Master Fund (Segregated Master Portfolio B) and Waqas Khatri — report beneficial ownership of 294,361 shares of SeaStar Medical Holding Corp common stock. The filing states these shares are issuable upon exercise of warrants and that the issuable shares are subject to a 9.99% beneficial ownership blocker. The calculation of the 2.56% holding uses 11,203,752 shares outstanding as the reference base.
This ownership is held through an investment vehicle managed by Ayrton Capital, with sole voting and dispositive power reported for each reporting person. The statement certifies the holdings were acquired and are held in the ordinary course of business.
SeaStar Medical Holding Corporation is registering the resale of up to 10,917,218 shares of common stock held by selling securityholders, comprised principally of shares issuable upon exercise of multiple private-placement warrants issued in July and August 2025. The company had 27,914,596 shares outstanding as of August 5, 2025 and would have 38,831,814 shares outstanding if all related warrants are exercised. SeaStar is a commercial-stage medical device company whose Selective Cytopheretic Device (SCD) received FDA Humanitarian Device Exemption approval for pediatric acute kidney injury on February 21, 2024 and shipped its first commercial pediatric SCD in July 2024. The SCD has received Breakthrough Device Designation for six indications and is in a pivotal adult AKI trial. Financially, the company reported an accumulated deficit of $143.3 million and negative working capital of $0.2 million as of March 31, 2025, and its auditors noted substantial doubt about its ability to continue as a going concern. Recent financings include registered direct offerings and concurrent warrant placements in July and August 2025. Nasdaq has previously issued compliance notices and the company currently faces a minimum bid price deficiency notice with a cure period to January 27, 2026.
SeaStar Medical Holding Corporation disclosed it has resumed an at-the-market equity offering after suspending sales on July 10, 2025. The company previously sold an aggregate of $6.8 million of common stock under the ATM program and had earlier terminated the continuous offering tied to an initial aggregate offering price of $25,000,000. As of August 8, 2025, SeaStar will resume sales under the Company’s effective Form S-3 for an additional aggregate offering price of $2,166,305. Proceeds, if any, will be used for general corporate purposes, and there is no minimum offering amount so total shares and proceeds are not determinable. Legal opinion and related exhibits are filed with the report.